Ivermectin 12 mg, 100 Tablets (1 Pack) — TM Iverheal

Iverheal 12 (Ivermectin)

Iverheal 12 is a pharmaceutical-grade formulation of Ivermectin (12 mg per tablet), manufactured by Healing Pharma India Pvt. Ltd. under USP standards. In modern off-label research and drug-repurposing frameworks, Ivermectin is extensively evaluated as a pleiotropic, multi-targeted agent with applications in preventive oncology, cancer stem cell eradication, and the reversal of multi-drug resistance. This listing covers a full box of 100 tablets (10 blisters × 10 tablets) — the standard quantity for extended and multi-arm research protocols.

General Pharmaceutical & Manufacturer Information

• Brand Name: Iverheal 12
• Active Ingredient: Ivermectin IP/USP
• Dosage: 12 mg of Ivermectin per uncoated tablet
• Form: Oral tablets (uncoated)
• Package Size: 1 Pack — 100 tablets (10 blisters × 10 tablets)
• Manufacturer: Healing Pharma India Pvt. Ltd.
• CAS Number: 70288-86-7
• Molecular Formula: C48H74O14 (Ivermectin B1a) / C47H72O14 (Ivermectin B1b)

Therapeutic & Off-Label Mechanisms in Oncology Research

In translational oncology and repurposed therapeutic protocols, Ivermectin demonstrates activity against several key pathways of tumour survival and proliferation:

• Eradication of Cancer Stem Cells (CSCs): Disrupts key stemness pathways including Wnt/β-catenin, YAP1 and PAK1. By targeting CSC sub-populations it inhibits self-renewal and reduces tumour recurrence potential in preclinical models.
• Mitochondrial Stress & Apoptosis Induction: Causes mitochondrial membrane hyperpolarisation and induces intracellular reactive oxygen species (ROS) generation, selectively triggering energy depletion and caspase-dependent apoptotic cascades in malignant cells.
• Importin α/β1 Nuclear Transport Blockade: Inhibits the importin α/β1 heterodimer, blocking nuclear translocation of oncogenic transcription factors and of viral and cellular survival proteins.
• Reversal of Multidrug Resistance (MDR): Acts as a direct inhibitor of P-glycoprotein (ABCB1/P-gp) efflux pumps. This prevents the expulsion of chemotherapeutic agents, restoring sensitivity and increasing intracellular drug accumulation in resistant tumour cell lines.
• Inhibition of Tumour Angiogenesis & Autophagy Regulation: Downregulates Akt/mTOR signalling to induce protective or cytotoxic autophagy depending on context, while suppressing microvascular endothelial proliferation.

Scientific Context & References

1. Antitumour Mechanisms & Wnt Modulation: Research published in Pharmacological Research and the Journal of Experimental & Clinical Cancer Research details Ivermectin’s capacity to block Wnt/β-catenin and PAK1 signalling, leading to tumour growth inhibition.
2. P-gp Pump Inhibition: Studies in Molecular Pharmacology establish Ivermectin as a high-affinity substrate and inhibitor of P-glycoprotein, supporting its evaluation in combination strategies against multi-drug-resistant tumour phenotypes.
3. Nuclear Transport Blockade: Peer-reviewed data in Antiviral Research and the Biochemical Journal document its specific binding to importin α/β1, arresting the nucleocytoplasmic transport mechanisms used by oncogenic proteins.

Storage & Handling

• Store at a temperature not exceeding 30 °C.
• Protect from light and moisture.
• Keep out of reach of children.

Strict Regulatory Disclaimer: This product is intended solely for laboratory research, in vitro evaluation, and analytical purposes. We do not provide medical advice, recommend specific protocols, or guarantee any therapeutic results. Nothing stated herein should be construed as a medical recommendation or a guarantee of efficacy in treating, curing, or preventing any disease, including cancer. Any practical application of this compound must be strictly validated by independent research and overseen by a qualified professional.